ES2135411T3 - Proteinas osp a de subgrupos de borrelia burgdorferi, genes codificantes y vacunas. - Google Patents

Proteinas osp a de subgrupos de borrelia burgdorferi, genes codificantes y vacunas.

Info

Publication number
ES2135411T3
ES2135411T3 ES92917879T ES92917879T ES2135411T3 ES 2135411 T3 ES2135411 T3 ES 2135411T3 ES 92917879 T ES92917879 T ES 92917879T ES 92917879 T ES92917879 T ES 92917879T ES 2135411 T3 ES2135411 T3 ES 2135411T3
Authority
ES
Spain
Prior art keywords
vaccines
osp
subgroups
proteins
borrelia burgdorferi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917879T
Other languages
English (en)
Inventor
Yves Lobet
Markus Simon
Ulrich Schaible
Reinhard Wallich
Michael Kramer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Deutsches Krebsforschungszentrum DKFZ
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
SmithKline Beecham Biologicals SA
Deutsches Krebsforschungszentrum DKFZ
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2135411(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919117602A external-priority patent/GB9117602D0/en
Priority claimed from GB919122301A external-priority patent/GB9122301D0/en
Priority claimed from GB929211317A external-priority patent/GB9211317D0/en
Priority claimed from GB929211318A external-priority patent/GB9211318D0/en
Application filed by SmithKline Beecham Biologicals SA, Deutsches Krebsforschungszentrum DKFZ, Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical SmithKline Beecham Biologicals SA
Application granted granted Critical
Publication of ES2135411T3 publication Critical patent/ES2135411T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DESCRIBE LA NUEVA BORRELIA , LOS ANTIGENES OSPA DERIVADOS DE LA MISMA, LOS CUALES EXHIBEN UNA PEQUEÑA HOMOLOGIA CON LAS OSPA CONOCIDAS Y SON UTILES COMO VACUNAS Y REAGENTES DE DIAGNOSTICO. LAS VACUNAS MULTICOMPONENTES ESTAN BASADAS EN OSPA DE DIFERENTES GRUPOS DE BORRELIA.
ES92917879T 1991-08-15 1992-08-11 Proteinas osp a de subgrupos de borrelia burgdorferi, genes codificantes y vacunas. Expired - Lifetime ES2135411T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919117602A GB9117602D0 (en) 1991-08-15 1991-08-15 Novel antigens
GB919122301A GB9122301D0 (en) 1991-10-21 1991-10-21 Novel antigens
GB929211317A GB9211317D0 (en) 1992-05-28 1992-05-28 Novel antigens
GB929211318A GB9211318D0 (en) 1992-05-28 1992-05-28 Vaccines

Publications (1)

Publication Number Publication Date
ES2135411T3 true ES2135411T3 (es) 1999-11-01

Family

ID=27450728

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917879T Expired - Lifetime ES2135411T3 (es) 1991-08-15 1992-08-11 Proteinas osp a de subgrupos de borrelia burgdorferi, genes codificantes y vacunas.

Country Status (14)

Country Link
US (2) US6113914A (es)
EP (4) EP0878545A3 (es)
JP (1) JPH07501687A (es)
AT (1) ATE181572T1 (es)
AU (1) AU666326B2 (es)
CA (1) CA2115554A1 (es)
DE (1) DE69229476T2 (es)
DK (1) DK0598816T3 (es)
ES (1) ES2135411T3 (es)
GR (1) GR3031237T3 (es)
MX (1) MX9204685A (es)
NZ (1) NZ243952A (es)
PT (1) PT100781B (es)
WO (1) WO1993004175A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054296A (en) 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US6676942B1 (en) * 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
BE1006728A3 (fr) * 1993-02-19 1994-11-29 Wallone Region Sondes d'acides nucleiques specifiques au spirochete borrelia burgdorferi.
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
DE69535059T2 (de) * 1994-04-11 2007-01-18 Wyeth Holdings Corp. Borrelia burgdorferi bacterin
US6251405B1 (en) * 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
DE19629543C2 (de) * 1996-07-22 1999-02-11 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
DE19632862B4 (de) 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
US7083796B2 (en) 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20040086524A1 (en) * 1999-09-17 2004-05-06 Kuzyk Michael A. Vaccines and agents for inducing immunity in fish against rickettsial diseases, and associated preventative therapy
NO329958B1 (no) * 1999-09-17 2011-01-31 Pfizer Canada Inc Anvendelse av en immunogen mengde av OspA-lipoprotein fra Piscirickettsia salmonis, OspA-antigen, og immunogene promiskuose TCE i et OspA-kimaert fusjonsprotein, for fremstilling av medikamenter, og immunologisk in vitro-fremgangsmate for deteksjon av humoralt antistoff mot OspA eller P. salmonis.
US6299968B1 (en) * 1999-11-20 2001-10-09 Intertape Inc. General purpose multilayer film products
ATE381575T1 (de) * 2000-08-18 2008-01-15 Univ New York State Res Found Veränderte borrelia burgdorferi ospa
US20050058661A1 (en) * 2002-10-18 2005-03-17 Sykes Kathryn F. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus Borrelia
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
EP1981513B1 (en) 2006-01-19 2015-05-27 Mary Kay, Inc. Compositions comprising kakadu plum extract or acai berry extract
UA99719C2 (ru) 2006-11-03 2012-09-25 Шеринг-Плау Лтд. Вакцина для собак против болезни лайма
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US8426163B2 (en) * 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US7833776B2 (en) 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
EP2711021B1 (en) 2008-05-02 2016-03-09 BliNK Therapeutics Limited Products and methods for stimulating an immune response
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP2445927B1 (en) * 2009-06-22 2014-04-23 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
US8048456B2 (en) 2009-08-28 2011-11-01 Mary Kay Inc. Skin care formulations
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
EP2545071A2 (en) 2010-03-09 2013-01-16 Maksyutov, Amir Polyepitope constructs and methods for their preparation and use
AU2011252844B2 (en) 2010-05-14 2014-07-03 Baxalta GmbH Chimeric OspA genes, proteins, and methods of use thereof
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
WO2013067448A2 (en) 2011-11-03 2013-05-10 Vca Antech Inc. Compositions and methods to detect various infectious organisms
UY34745A (es) * 2012-04-18 2013-11-29 Zoetis Llc Vacunas y procedimientos para tratar la enfermedad de lyme en perros
US9562079B2 (en) 2012-04-18 2017-02-07 Zoetis Services Llc Vaccines and methods to treat lyme disease in dogs
AU2013293448A1 (en) 2012-07-27 2015-02-05 Baxalta GmbH Compositions comprising chimeric OspA molecules and methods of use thereof
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DK425789A (da) * 1988-08-31 1990-03-01 Smithkline Beecham Corp Vaccinale polypeptider
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
CA2084413A1 (en) * 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
JPH07502646A (ja) * 1991-10-21 1995-03-23 メディミューン，インコーポレーテッド リポタンパク質の分泌シグナルをコード化するｄｎａを含む細菌発現ベクター
ES2194010T3 (es) * 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.

Also Published As

Publication number Publication date
AU2432792A (en) 1993-03-16
EP0878545A3 (en) 1998-12-16
EP0598816B1 (en) 1999-06-23
DE69229476T2 (de) 2000-03-16
EP0878545A2 (en) 1998-11-18
WO1993004175A1 (en) 1993-03-04
EP0598816A1 (en) 1994-06-01
NZ243952A (en) 1995-06-27
EP0874051A3 (en) 1998-11-04
US5942236A (en) 1999-08-24
GR3031237T3 (en) 1999-12-31
US6113914A (en) 2000-09-05
DK0598816T3 (da) 1999-11-22
PT100781A (pt) 1993-09-30
CA2115554A1 (en) 1993-03-04
PT100781B (pt) 1999-07-30
JPH07501687A (ja) 1995-02-23
AU666326B2 (en) 1996-02-08
HK1012420A1 (en) 1999-07-30
EP0874051A2 (en) 1998-10-28
EP0877085A1 (en) 1998-11-11
DE69229476D1 (de) 1999-07-29
ATE181572T1 (de) 1999-07-15
MX9204685A (es) 1994-06-30

Similar Documents

Publication Publication Date Title
ES2135411T3 (es) Proteinas osp a de subgrupos de borrelia burgdorferi, genes codificantes y vacunas.
ES2151921T3 (es) Analogo de dolastatina.
ES2194010T3 (es) Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
FI903201A0 (fi) Funktionell genom rekombination framstaelld syntetisk proteinpolymer.
DE69232537D1 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
PT920510E (pt) Quimeras de gnrh-leucotoxina
FR2598149B1 (fr) Compositions de polymeres sequences.
ATE448301T1 (de) Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
MX9203379A (es) Proteinas producidas por los linfocitos humanos, secuencia de adn que codifica para estas proteinas y composiciones farmaceuticas que las contienen.
ATE48005T1 (de) Sternfoermige akrylpolymere.
ATE295416T1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
DE69428911D1 (de) Selektive hydrierung von hoch ungesättigten verbindungen in kohlenwasserstoffströmen
ES2046462T3 (es) Marcadores de activacion de celulas "t".
NO900348L (no) Hybrid kunststoffmaterialer.
ES2054699T3 (es) Pigmentos que contienen grupos de piperidilo.
BR9004301A (pt) Polimero de enxerto,mistura endurecivel por luz;bem como material de registro
DK0726955T3 (da) Kimære proteiner, som omfatter Borreliapolypeptider, og anvendelser heraf
ES2174835T3 (es) Carboxilasa dependiente de la vitamina k.
NL7711502A (nl) Uit kunststof vervaardigde houder, in het bijzonder emmer.
DE69112260D1 (de) Gellan-Gummi-Fasern.
DE68916711D1 (de) Vulkanisierte Äthylen-Alpha-Olefin-Copolymer-Gummi-Zusammensetzung.
FI941851A7 (fi) Borrelia Burgdorferi -organismin (Bb) virulenssiin liittyvät proteiini t
BR8901275A (pt) Composicao detergente aquosa,abrasiva,homogenea,despejavel
ES2062006T3 (es) Un psti humano modificado.
FI902803A7 (fi) DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 598816

Country of ref document: ES